TCHL a phase II neo-adjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab), TCL (Docetaxel, Carboplatin and Lapatinib) and the combination TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in ErbB2+ve breast cancer patients

Hdl Handle:
http://hdl.handle.net/10147/142451
Title:
TCHL a phase II neo-adjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab), TCL (Docetaxel, Carboplatin and Lapatinib) and the combination TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in ErbB2+ve breast cancer patients
Issue Date:
16-Sep-2011
URI:
http://hdl.handle.net/10147/142451
Keywords:
BREAST CANCER
Research Methodology:
TCHL Phase II neo-adjuvant study
Duration of Research:
Trial on hold.
Ethical Approval:
Yes
Start Date:
2010-12
Principal Investigator:
O'Connor, Miriam Dr.

Full metadata record

DC FieldValue Language
dc.date.accessioned2011-09-16T10:16:02Z-
dc.date.available2011-09-16T10:16:02Z-
dc.date.issued2011-09-16T10:16:02Z-
dc.identifier.urihttp://hdl.handle.net/10147/142451-
dc.subjectBREAST CANCERen
dc.titleTCHL a phase II neo-adjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab), TCL (Docetaxel, Carboplatin and Lapatinib) and the combination TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in ErbB2+ve breast cancer patientsen
dc.type.qualificationlevelN/Aen
cr.methodologyTCHL Phase II neo-adjuvant studyen
cr.durationTrial on hold.en
cr.approval.ethicalYesen
cr.contributor.principalO'Connor, Miriam Dr.en
cr.date.start2010-12-
dc.description.provinceMunster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.